Genvor’s AGM182 Peptide Tech Validated in USDA-Backed Study

Event summary

  • Genvor’s AGM182 antifungal peptide technology validated in peer-reviewed study published in PhytoFrontiers™ on February 11, 2026.
  • Transgenic corn expressing AGM182 showed 76-98% reduction in aflatoxin contamination in greenhouse trials.
  • USPTO granted U.S. Patent No. 12,458,684 for AGM182 technology in November 2025.
  • Study conducted in collaboration with USDA-ARS and Tuskegee University, with no adverse effects on plant growth or yield observed.

The big picture

Genvor’s validation of AGM182 technology comes at a time when agricultural biotech is increasingly focused on reducing chemical inputs and enhancing crop resilience. The peer-reviewed study and patent protection position Genvor to capitalize on the growing demand for sustainable crop protection solutions, particularly in regions heavily impacted by aflatoxin contamination. The collaboration with USDA-ARS underscores the strategic importance of public-private partnerships in advancing agricultural innovation.

What we're watching

Commercialization Pace
How quickly Genvor can advance licensing discussions with agricultural partners following the peer-reviewed validation and patent protection.
Market Adoption
Whether the broad-spectrum activity against Fusarium species and other pathogens will drive wider commercial interest beyond aflatoxin resistance.
Regulatory Approval
The pace at which regulatory approvals for AGM182-enabled crops will be secured, given the mammalian safety profile and proven efficacy.